ClinicalTrials.gg
RecruitingNCT07330622POL-CTOUpdated Jan 9, 2026

Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions

An observational study in Coronary Occlusion and Percutaneous Coronary Intervention, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 21 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the safety, efficacy, and clinical outcomes of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) in patients treated in contemporary clinical practice in Poland.

The main questions it aims to answer are:

  • What are the rates of procedural success and periprocedural complications of CTO PCI in routine clinical practice?
  • How do CTO PCI strategies and techniques, intravascular imaging, different treatment strategies, and mechanical circulatory support affect clinical outcomes?
  • How do clinical outcomes differ among different patient subgroups?
  • Can artificial intelligence-based analysis predict clinical and quality-of-life outcomes after CTO PCI?

Patients undergoing CTO PCI as part of their standard medical care will be prospectively enrolled in a national, multicenter registry, with clinical, procedural, and follow-up data collected to evaluate real-world outcomes.

Read the detailed description

Coronary chronic total occlusions (CTO) are diagnosed in approximately 20% of patients undergoing invasive coronary angiography, and their presence is associated with significantly reduced quality of life and worse long-term prognosis compared with patients without a CTO. Successful CTO recanalization improves quality of life, regional and global left ventricular function, and reduces myocardial ischemia in most patients. Over the past decade, the success rate of percutaneous coronary intervention (PCI) for CTO has increased substantially, largely due to advances in dedicated equipment and specialized procedural techniques. Concurrently, there is a growing need to evaluate the safety and effectiveness of contemporary CTO PCI techniques in selected patient populations.

The aim of the POL-CTO registry is to expand current knowledge regarding the safety and efficacy of CTO PCI in the contemporary Polish population across a broad range of clinical scenarios. Specifically, the registry will examine the incidence and management of periprocedural complications, as well as the impact of post-procedural cardiac injury markers on clinical outcomes. Comparative analyses of PCI performed with versus without intravascular imaging, along with different treatment strategies (drug-coated balloon [DCB], drug-eluting stent [DES], or hybrid approaches), will be conducted. Additional objectives include evaluating the safety of PCI with mechanical circulatory support and predicting quality-of-life improvement using artificial intelligence-based analysis of baseline electrocardiograms. Finally, the study will focus on CTO PCI outcomes in high-risk subgroups, including patients with low ejection fraction, frailty syndrome, severe coronary calcification, diabetes, prior transcatheter aortic valve implantation, prior coronary artery bypass grafting, and in-stent CTO.

02

Conditions studied

  • Coronary Occlusion
  • Percutaneous Coronary Intervention

Keywords

  • coronary artery disease
  • percutaneous coronary intervention
  • coronary chronic total occlusion
03

In context

Coronary Occlusion

71 studies on the registry are indexed under Coronary Occlusion; 11 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 659 across 26 observational studies indexed under Coronary Occlusion.

Browse Coronary Occlusion studies →

Lead sponsor

National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients undergoing CTO PCI at participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing CTO PCI based on clinical grounds

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Patient's refusal to participate in the registry
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Technical success

    Achievement of Thrombolysis In Myocardial Infarction grade 3 flow in all ≥2.5-mm distal branches with \<30% residual stenosis.

    Time frame: procedural (1 day)

Secondary outcomes

  1. Total procedure time

    Total procedure time in minutes.

    Time frame: procedural (1 day)

  2. Fluoroscopy time

    Fluoroscopy time in minutes.

    Time frame: procedural (1 day)

  3. Radiation dose

    Total radiation dose in Gy and uGycm2.

    Time frame: procedural (1 day)

  4. Contrast volume

    Total contrast volume in mL.

    Time frame: procedural (1 day)

  5. Number and type of procedural complications

    Total number and specification of procedural complications (death, non-fatal myocardial infarction, cardiac tamponade requiring pericardiocentesis, coronary perforation, stroke, major bleeding according to Bleeding Academic Research Consortium).

    Time frame: procedural (1 day)

  6. Successful guidewire crossing through CTO

    Rate of successful guidewire crossing through CTO.

    Time frame: procedural (1 day)

  7. Time of successful guidewire crossing

    Time of successful guidewire crossing through CTO in minutes defined as the time from starting primary CTO PCI strategy to the time of successful CTO recanalization using any technique.

    Time frame: procedural (1 day)

  8. Target lesion failure

    Total number of cardiac death, target vessel-related myocardial infarction or clinically-driven target lesion revascularization

    Time frame: in-hospital (2-5 days)

  9. Target lesion failure

    otal number of cardiac death, target vessel-related myocardial infarction or clinically-driven target lesion revascularization

    Time frame: 1 year

  10. Death

    Any death

    Time frame: 1 year

07

Study locations

21 of 21 sites recruiting
  • Medical University of Białystok
    Bialystok, Poland
    Recruiting
    • Grzegorz Mężynski · Contact
  • Szpital Zachodni
    Grodzisk Mazowiecki, Poland
    Recruiting
    • Piotr Pawluczuk · Contact
  • Specialist Hospital in Inowrocław
    Inowrocław, Poland
    Recruiting
    • Marek Radomski · Contact
  • Medical University of Silesia
    Katowice, Poland
    Recruiting
    • Paweł Gąsior · Contact
    • Mariusz Łebek · Contact
  • Institute of Cardiology
    Krakow, Poland
    Recruiting
    • Leszek Bryniarski · Contact
  • St. John Paul II Hospital
    Krakow, Poland
    Recruiting
    • Daniel Rzeźnik · Contact
    • Jacek Legutko · Contact
  • Copper Health Centre Inc.
    Lubin, Poland
    Recruiting
    • Adrian Włodarczak · Contact
  • 1st Military Clinical Hospital
    Lublin, Poland
    Recruiting
    • Grzegorz Sobieszek · Contact
  • Hospital of the Ministry of the Interior and Administration
    Lublin, Poland
    Recruiting
    • Jakub Drozd · Contact
  • University of Applied Science in Nowy Sącz
    Nowy Sącz, Poland
    Recruiting
    • Aleksander Zeliaś · Contact
  • Masovian Specialist Hospital
    Ostrołęka, Poland
    Recruiting
    • Paweł Radecki · Contact
  • Poznań University of Medical Sciences
    Poznan, Poland
    Recruiting
    • Sylwia Iwańczyk · Contact
    • Wojciech Skorupski · Contact
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej w Puławach
    Puławy, Poland
    Recruiting
    • Marek Jankiewicz · Contact
  • Specialistic Hospital
    Radom, Poland
    Recruiting
    • Wojciech Dworzański · Contact
  • The Ministry of Internal Affairs and Administration Hospital
    Rzeszów, Poland
    Recruiting
    • Piotr Wańczura · Contact
    • Wojciech Stećko · Contact
  • Military Institute of Medicine - National Research Institute
    Warsaw, Poland
    Recruiting
    • Piotr Kwiatkowski · Contact
    • Michał Malinowski · Contact
  • National Institute of Cardiology
    Warsaw, Poland
    Recruiting
    • Maksymilian Opolski · Contact
    • Hubert Borzuta · Sub investigator
    • Filip Kiljański · Sub investigator
  • The Doctor Sokolowski Hospital
    Wałbrzych, Poland
    Recruiting
    • Michał Kryjak · Contact
  • Military Hospital in Wrocław
    Wroclaw, Poland
    Recruiting
    • Krzysztof Ściborski · Contact
  • University Hospital in Wroclaw
    Wroclaw, Poland
    Recruiting
    • Wojciech Zimoch · Contact
  • Provincial Hospital in Łomża
    Łomża, Poland
    Recruiting
    • Grzegorz Horszczaruk · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Jan 9, 2026
StartActual
May 21, 2025
Primary completionEst.
May 2026
CompletionEst.
Jun 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07330622
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Collaborators
Polish Cardiac Society
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
May 21, 2025
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 9, 2026

Study contacts

Maksymilian Opolski, MD, PhD
Contact
mopolski@ikard.pl
0048223434127
Izabela Majewska
Contact
imajewska@ikard.pl

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion